Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Fase 2-plattformstudie av nye immunterapikombinasjoner som førstelinjebehandling hos deltakere med PD-L1 positiv tilbakevendende/metastatisk plateepitelkarsinom i hode og nakke

23. september 2026 oppdatert av: GlaxoSmithKline

En fase 2, randomisert, åpen plattformstudie ved bruk av en masterprotokoll for å evaluere nye immunterapikombinasjoner som førstelinjebehandling hos deltakere med tilbakevendende/metastaserende PD-L1 positivt plateepitelkarsinom i hode og nakke

The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

316

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Buenos Aires, Argentina, C1426ABP
        • GSK Investigational Site
      • Capital Federal, Argentina, C1181ACH
        • GSK Investigational Site
      • Ciudad Autonoma de Bueno, Argentina, C1056ABI
        • GSK Investigational Site
      • Córdoba, Argentina, 5000
        • GSK Investigational Site
      • Florida, Argentina, B1602DQD
        • GSK Investigational Site
      • Mendoza, Argentina, M5500AYB
        • GSK Investigational Site
      • San Juan, Argentina, 5400
        • GSK Investigational Site
      • Santa Fe, Argentina, 3000
        • GSK Investigational Site
      • Santo André, Brasil, 09060-650
        • GSK Investigational Site
      • São Paulo, Brasil, 01246-000
        • GSK Investigational Site
      • São Paulo, Brasil, 01221-020
        • GSK Investigational Site
    • Alberta
      • Calgary, Alberta, Canada, T2N 5G2
        • GSK Investigational Site
      • Edmonton, Alberta, Canada, T6G 1Z2
        • GSK Investigational Site
    • Ontario
      • Toronto, Ontario, Canada, M4N 3M5
        • GSK Investigational Site
      • Toronto, Ontario, Canada, M5G 2M9
        • GSK Investigational Site
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • GSK Investigational Site
      • Herlev, Danmark
        • GSK Investigational Site
      • Turku, Finland, 20520
        • GSK Investigational Site
    • Connecticut
      • New Haven, Connecticut, Forente stater, 06511
        • GSK Investigational Site
    • Iowa
      • Iowa City, Iowa, Forente stater, 52242
        • GSK Investigational Site
    • Missouri
      • St Louis, Missouri, Forente stater, 63110-1010
        • GSK Investigational Site
    • Ohio
      • Columbus, Ohio, Forente stater, 43210
        • GSK Investigational Site
    • Wisconsin
      • Milwaukee, Wisconsin, Forente stater, 53226
        • GSK Investigational Site
      • Bordeaux, Frankrike, 33075
        • GSK Investigational Site
      • Caen, Frankrike, 14075
        • GSK Investigational Site
      • Marseille, Frankrike, 13005
        • GSK Investigational Site
      • Paris, Frankrike, 75005
        • GSK Investigational Site
      • Rouen, Frankrike, 76038
        • GSK Investigational Site
      • Villejuif, Frankrike, 94805
        • GSK Investigational Site
      • Haidari - Athens, Hellas, 12462
        • GSK Investigational Site
      • Marousi, Hellas
        • GSK Investigational Site
    • Central Macedonia
      • Panórama, Central Macedonia, Hellas, 552 36
        • GSK Investigational Site
      • Bari, Italia, 70124
        • GSK Investigational Site
      • Bologna, Italia, 40139
        • GSK Investigational Site
      • Florence, Italia, 50134
        • GSK Investigational Site
      • Genova, Italia, 16132
        • GSK Investigational Site
      • Milan, Italia, 20133
        • GSK Investigational Site
      • Naples, Italia, 80131
        • GSK Investigational Site
      • Novara, Italia, 28100
        • GSK Investigational Site
      • Padova, Italia, 35128
        • GSK Investigational Site
      • Roma, Italia, 00168
        • GSK Investigational Site
      • Roma, Italia, 00144
        • GSK Investigational Site
    • MI
      • Rozzano, MI, Italia, 20089
        • GSK Investigational Site
      • Aichi, Japan, 464-8681
        • GSK Investigational Site
      • Chiba, Japan, 277-8577
        • GSK Investigational Site
      • Hyōgo, Japan, 650-0017
        • GSK Investigational Site
      • Osaka, Japan, 541-8567
        • GSK Investigational Site
      • Saitama, Japan, 350-1298
        • GSK Investigational Site
      • Shizuoka, Japan, 411-8777
        • GSK Investigational Site
      • Tokyo, Japan, 104-0045
        • GSK Investigational Site
      • Oslo, Norge, 0379
        • GSK Investigational Site
      • Bielsko-Biala, Polen, 43-300
        • GSK Investigational Site
      • Katowice, Polen, 40-514
        • GSK Investigational Site
      • Krakow, Polen, 31-826
        • GSK Investigational Site
      • Przemyśl, Polen, 37-700
        • GSK Investigational Site
      • Siedlce, Polen, 08-110
        • GSK Investigational Site
      • Warsaw, Polen, 04-141
        • GSK Investigational Site
      • Almada, Portugal, 2801-951
        • GSK Investigational Site
      • Lisbon, Portugal, 1649-035
        • GSK Investigational Site
      • Porto, Portugal, 4099-001
        • GSK Investigational Site
      • Porto, Portugal, 4200-072
        • GSK Investigational Site
      • Brasov, Romania, 500283
        • GSK Investigational Site
      • Bucharest, Romania, 020142
        • GSK Investigational Site
      • Bucharest, Romania, 022328
        • GSK Investigational Site
      • Bucharest, Romania, 030171
        • GSK Investigational Site
      • Bucharest, Romania, 30463
        • GSK Investigational Site
      • Craiova, Romania, 200542
        • GSK Investigational Site
      • Floreşti, Romania, 407280
        • GSK Investigational Site
      • Iași, Romania, 700483
        • GSK Investigational Site
      • Oradea, Romania, 410469
        • GSK Investigational Site
      • Piteşti, Romania, 110283
        • GSK Investigational Site
      • Suceava, Romania, 720214
        • GSK Investigational Site
      • Barcelona, Spania, 08035
        • GSK Investigational Site
      • Barcelona, Spania, 08907
        • GSK Investigational Site
      • Barcelona, Spania, 08023
        • GSK Investigational Site
      • Jaén, Spania, 23007
        • GSK Investigational Site
      • Madrid, Spania, 28041
        • GSK Investigational Site
      • Madrid, Spania, 28040
        • GSK Investigational Site
      • Madrid, Spania, 28034
        • GSK Investigational Site
      • Madrid, Spania, 28010
        • GSK Investigational Site
      • Pozuelo de AlarcOn Madr, Spania, 28223
        • GSK Investigational Site
      • Salamanca, Spania, 37007
        • GSK Investigational Site
      • Santander, Spania, 39008
        • GSK Investigational Site
      • Valencia, Spania, 46009
        • GSK Investigational Site
      • Zaragoza, Spania, 50009
        • GSK Investigational Site
      • Daegu, Sør -Korea, 42601
        • GSK Investigational Site
      • Seongnam-si Gyeonggi-do, Sør -Korea, 13620
        • GSK Investigational Site
      • Seoul, Sør -Korea, 138-736
        • GSK Investigational Site
      • Seoul, Sør -Korea, 03722
        • GSK Investigational Site
      • Suwon Kyunggi-do, Sør -Korea, 443-721
        • GSK Investigational Site
      • Changhua, Taiwan, 500
        • GSK Investigational Site
      • Tainan, Taiwan, 704
        • GSK Investigational Site
      • Taipei, Taiwan, 11217
        • GSK Investigational Site
      • Taipei, Taiwan, 10002
        • GSK Investigational Site
      • Ankara, Tyrkia (Türkiye), 06100
        • GSK Investigational Site
      • Istanbul, Tyrkia (Türkiye), 34662
        • GSK Investigational Site
      • Izmir, Tyrkia (Türkiye), 35040
        • GSK Investigational Site
      • Aachen, Tyskland, 52074
        • GSK Investigational Site
      • Berlin, Tyskland, 12203
        • GSK Investigational Site
      • Giessen, Tyskland, 35392
        • GSK Investigational Site
      • Hamburg, Tyskland, 20246
        • GSK Investigational Site
      • Regensburg, Tyskland, 93053
        • GSK Investigational Site
      • Ulm, Tyskland, 89075
        • GSK Investigational Site
    • Hesse
      • Frankfurt am Main, Hesse, Tyskland, 60488
        • GSK Investigational Site
    • North Rhine-Westphalia
      • Essen, North Rhine-Westphalia, Tyskland, 45122
        • GSK Investigational Site
      • Győr, Ungarn, 9024
        • GSK Investigational Site
      • Kecskemét, Ungarn, 6000
        • GSK Investigational Site
      • Pécs, Ungarn, 7624
        • GSK Investigational Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Have histologically or cytologically-confirmed HNSCC that is R/M and is considered incurable by local therapies. A) Subjects must not have had prior systemic therapy administered in the R/M setting. Chemoradiation therapy which was completed more than 4 months prior to signing consent if given as part of multimodal treatment for locally advanced disease is allowed B) The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx C) Subjects may not have a primary tumor site of nasopharynx (any histology)
  • Has measurable (target) disease based on RECIST 1.1 as determined by the investigator.
  • Has an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
  • Provides a tumor tissue sample obtained at the time of or after the initial diagnosis of R/M HNSCC. A fresh tumor tissue sample obtained within 90 days of screening is highly preferred, If fresh biopsy is not possible, an archival tumor specimen is acceptable unless it was obtained prior to administration of chemoradiation for the treatment of a participant's tumor. Needle or excisional biopsies or resected tissue is required. Cytological specimens such as fine needle aspirates, bone marrow samples, or cell blocks are not acceptable. Bone specimen is not acceptable.
  • Has tumor Programmed death ligand 1 (PD-L1) expression
  • If the primary tumor site is oropharyngeal carcinoma, the participant must have Human papillomavirus (HPV) results

Exclusion Criteria:

  • Has received prior therapy with any immune checkpoint inhibitors, including antibodies or drugs targeting Programmed death protein 1 (PD-1), PD-L1, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine based inhibitory motif domains (TIGIT), Cluster of differentiation (CD) 96, or other immune checkpoint pathways.
  • Participants with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, esophageal, colon, endometrial, cervical/dysplasia, melanoma, or breast) unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period.
  • Have active tumor bleeding or a high risk of bleeding (examples include but are not limited to radiographic evidence of major blood vessel invasion/infiltration or tumor demonstrates >90 degree abutment or encasement of a major vessel [carotid, jugular, bronchial artery] and/or exhibits other high-risk features such as arteriovenous fistula).
  • Has PD within 4 months of completion of curatively intended treatment for locoregionally advanced HNSCC
  • Participants with any carcinomatous meningitis or leptomeningeal spread and those with uncontrolled or symptomatic Central Nervous System (CNS) metastases
  • Active autoimmune disease that has required systemic disease-modifying or immunosuppressive treatment within the last 2 years. (Stable, medically managed autoimmune endocrinopathies are acceptable if participant otherwise meets entry criteria.)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Dostarlimab monoterapi

Dostarlimab will be administered.

Eksperimentell: Delstudie 1: Dostarlimab og Belrestotug

Dostarlimab will be administered.

Belrestotug will be administered.

Eksperimentell: Delstudie 2: Dostarlimab og nelistotug

Dostarlimab will be administered.

Nelistotug will be administered.

Eksperimentell: Delstudie 3: Dosarlimab og Belrestotug og nelistotug

Dostarlimab will be administered.

Belrestotug will be administered.

Nelistotug will be administered.

Eksperimentell: Substudie 4: Dostarlimab og Remzistotug

Dostarlimab will be administered.

Remzistotug will be administered.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Confirmed Objective Response Rate (ORR) compared between Sub studies and Dostarlimab monotherapy
Tidsramme: Up to approximately 24 months

Confirmed ORR is defined as the percentage of participants achieving confirmed Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator assessment.

Up to approximately 24 months

Sekundære resultatmål

Resultatmål
Tidsramme
Antall deltakere med TEAE som fører til doseendringer eller seponering av studieintervensjon
Tidsramme: Opptil ca 24 måneder
Opptil ca 24 måneder
Antall deltakere med klinisk signifikante funn i vitale tegn, elektrokardiogram (EKG) og laboratorietestparametre
Tidsramme: Opptil ca 24 måneder
Opptil ca 24 måneder
Antall deltakere med akutte behandlingsbivirkninger (AEs), behandlingsfremvoksende alvorlige bivirkninger (SAE) og behandlingsfremvoksende bivirkninger av spesiell interesse (AESI)
Tidsramme: Opptil ca 24 måneder
Opptil ca 24 måneder

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Studieleder: GSK Clinical Trials, GlaxoSmithKline

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

14. november 2023

Primær fullføring (Faktiske)

10. september 2026

Studiet fullført (Antatt)

31. desember 2027

Datoer for studieregistrering

Først innsendt

21. september 2023

Først innsendt som oppfylte QC-kriteriene

29. september 2023

Først lagt ut (Faktiske)

2. oktober 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

24. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

23. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 219885
  • 2023-503428-24 (Registeridentifikator: CTIS)
  • 2023 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

IPD-delingstidsramme

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Tilgangskriterier for IPD-deling

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere